WO1996007652B1 - Calicheamicin mimics - Google Patents
Calicheamicin mimicsInfo
- Publication number
- WO1996007652B1 WO1996007652B1 PCT/US1995/011207 US9511207W WO9607652B1 WO 1996007652 B1 WO1996007652 B1 WO 1996007652B1 US 9511207 W US9511207 W US 9511207W WO 9607652 B1 WO9607652 B1 WO 9607652B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calicheamicin
- mimics
- represented
- following structure
- mimic
- Prior art date
Links
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical class C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 title claims abstract 5
- 230000003278 mimic Effects 0.000 claims 3
- 230000004913 activation Effects 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 abstract 1
Abstract
Synthetic calicheamicin mimics employ alternative activation triggers and trigger sites and include tethers for conjugation to DNA targeting systems.
Claims
AMENDED CLAIMS
[received by the International Bureau on 4 March 1996 (04.03.96); original claim 8 cancelled; original claims 2, 5 and 7 amended;
remaining claims unchanged (3 pages)] wherein R is selected from the group consisting of:
3. A calicheamicin mimic represented by the following structure:
6. A calicheamicin mimic represented by the following structure:
7. A calicheamicin mimic intermediate represented by the following structure:
R=OCOCH3,
R=OCOO(CH2)2SPh, R = OCOO(CH2)2SO2Ph, R = N 3 and
R = NHCOCH3.
8. [cancel]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU35037/95A AU3503795A (en) | 1994-09-07 | 1995-09-06 | Synthesis of proteins by native chemical ligation calicheamicin mimics |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/301,968 | 1994-09-07 | ||
| US08/301,968 US5550246A (en) | 1994-09-07 | 1994-09-07 | Calicheamicin mimics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996007652A1 WO1996007652A1 (en) | 1996-03-14 |
| WO1996007652B1 true WO1996007652B1 (en) | 1996-04-04 |
Family
ID=23165693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/011207 WO1996007652A1 (en) | 1994-09-07 | 1995-09-06 | Calicheamicin mimics |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5550246A (en) |
| AU (1) | AU3503795A (en) |
| WO (1) | WO1996007652A1 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2564197A (en) * | 1996-04-26 | 1997-11-19 | University Of Alberta | Synthesis of (+/-) - calicheamicinone, precursors, intermediates and derivatives |
| US6733998B1 (en) | 1998-12-07 | 2004-05-11 | Sloan-Kettering Institute For Cancer Research | Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto |
| JP4619651B2 (en) | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | Modified antibodies against prostate-specific membrane antigen and uses thereof |
| EP1868647A4 (en) | 2005-03-24 | 2009-04-01 | Millennium Pharm Inc | Antibodies that bind ov064 and methods of use therefor |
| AR076770A1 (en) | 2009-05-13 | 2011-07-06 | Genzyme Corp | ANTI-CD52 HUMAN IMMUNOGLOBULINS |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
| EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
| JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
| WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| AU2012323287B2 (en) | 2011-10-10 | 2018-02-01 | Xencor, Inc. | A method for purifying antibodies |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CN110981964B (en) | 2013-01-14 | 2023-09-15 | Xencor股份有限公司 | Novel heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| AU2014207549B2 (en) | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| AR095199A1 (en) | 2013-03-15 | 2015-09-30 | Genzyme Corp | ANTI-CD52 ANTIBODIES |
| EP3936521A1 (en) | 2013-03-15 | 2022-01-12 | Xencor, Inc. | Heterodimeric proteins |
| LT3055331T (en) | 2013-10-11 | 2021-03-25 | Oxford Bio Therapeutics Limited | Conjugated antibodies against ly75 for the treatment of cancer |
| KR102497443B1 (en) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Bispecific antibodies that bind to cd38 and cd3 |
| WO2016014984A1 (en) | 2014-07-24 | 2016-01-28 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| PE20171103A1 (en) | 2014-11-26 | 2017-08-07 | Xencor Inc | HETERODIMERIC ANTIBODIES THAT BIND TO CD3 AND CD38 |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| US10590158B2 (en) * | 2015-06-29 | 2020-03-17 | William Marsh Rice University | Total synthesis of shishijimicin A and analogs thereof |
| CN108699136B (en) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | Heterodimeric antibodies that bind CD3 and PSMA |
| RU2022104399A (en) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | BISPECIFIC ANTIBODIES-CHECKPOINT INHIBITORS |
| AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN110214148A (en) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | Bispecific heterodimer fusion protein containing IL-15/IL-15R α Fc fusion protein and PD-1 antibody fragment |
| MA49517A (en) | 2017-06-30 | 2020-05-06 | Xencor Inc | TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND AREAS OF ANTIGEN BINDING |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| JP2021502100A (en) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| JP2021506291A (en) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | Modified IL-2 FC fusion protein |
| CN112469477A (en) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | Heterodimeric antibodies binding to fibroblast activation proteins |
| CN112437777A (en) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | TIM-3 targeting heterodimeric fusion proteins comprising an IL-15/IL-15RA Fc fusion protein and a TIM-3 antigen binding domain |
| EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| SG11202013138RA (en) | 2018-07-02 | 2021-01-28 | Amgen Inc | Anti-steap1 antigen-binding protein |
| US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| KR20230154311A (en) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Heterodimeric antibodies binding to CD3 and GPC3 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264586A (en) * | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
-
1994
- 1994-09-07 US US08/301,968 patent/US5550246A/en not_active Expired - Fee Related
-
1995
- 1995-09-06 AU AU35037/95A patent/AU3503795A/en not_active Abandoned
- 1995-09-06 WO PCT/US1995/011207 patent/WO1996007652A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996007652B1 (en) | Calicheamicin mimics | |
| HK1023513A1 (en) | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods | |
| WO1997017945A3 (en) | Methods and compositions for the delivery of monomeric proteins | |
| DE69432758D1 (en) | Therapeutisch wirksame peptidderivate | |
| EP0764886A3 (en) | Naphthoquinone derivative and electrophotosensitive material using the same | |
| AU590210B2 (en) | Process for sizing paper with anionic hydrophobic sizing agents and cationic retention aids | |
| TR199701544T1 (en) | New dolastatin derivatives, their preparation and use. | |
| AU3635093A (en) | Motor vehicle for the shooting of a film in difficult and hilly ground | |
| MX9709398A (en) | N-aryl-1,2,4-triazolin-5-ones. | |
| AU6227996A (en) | Pleated package having a reinforced central region with pre-expanded pleats | |
| CA2272701A1 (en) | Glycolipid mimics and methods of use thereof | |
| EP0832566A3 (en) | Cheese sauce | |
| AU6500696A (en) | Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents | |
| CA2149164A1 (en) | Diatomaceous earth insecticidal composition | |
| TR199701335T1 (en) | Diatomaceous earth pest composition | |
| EP0779765A3 (en) | Hole-transporting material and use thereof | |
| AU3577295A (en) | Reagent for the determination of free radicals | |
| CA2181006A1 (en) | N,n-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dimaleate | |
| Enck et al. | Evaluation of proposals for changes in deer hunting regulations | |
| GB2108445A (en) | Fuel tank assembly | |
| EP0381916A3 (en) | An improved rifle | |
| KR920011535A (en) | Jump aids | |
| WO1993011731A3 (en) | Alicyclic peptidomimetics | |
| Ozarko | Marsh foraminifera from Nanaimo, British Columbia: infaunal habitat and taphonomic implications. | |
| HOWES | Real-time Ada design methodologies and their impact on performance(Final Report) |